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Summary New platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(l,1-cyclobutanedicarboxylato)plat-
inum(II) monohydrate (DWA21 14R) and its enantiomeric isomer, (+)-(S)-2-aminomethylpyrrolidine(l,1-
cyclobutanedicarboxylato)platinum(II) monohydrate (DWA21 14S), were compared in their antitumour effects
and nephrotoxicity-inducing activities. Both compounds were effective against the murine tumours L1210 and
Colon 26 by i.p. injection of 20-100mg kg-'. While DWA2114S showed marked increases in blood urea
nitrogen (BUN) and urinary protein and sugar in BDF, mice treated i.p. at the maximum tolerated dose,
DWA2114R showed no increases in these parameters. To clarify the difference of nephrotoxicity between the
isomers, tissue distribution was examined. Renal Pt concentration in DWA21 14S-treated mice was more than
5-fold higher compared with that in DWA2114R-treated mice 2h after i.p. injection of 80 mg kg-'. However,
there were no such marked differences in the lung, liver, heart, spleen and plasma. The low content of Pt in the
kidneys of DWA2114R-treated mice could explain its lower nephrotoxicity. The in vitro experiments for
uptake of the drugs into the cultured normal rat kidney cells and fresh splenocytes revealed that the Pt
amount in the cells treated with DWA21 14S, especially in the kidney cells, was much higher than DWA21 14R.
Cisplatin is one of the most important anticancer drugs in
chemotherapy of the last few years. This drug is mainly
active against testicular and ovarian neoplasms, and has also
been used with some success against tumours of the lung,
bladder, cervix, head and neck (Rozencweig et al., 1977).
However, severe side effects such as nausea, vomiting, neph-
rotoxicity and neurotoxicity have been found to accompany
the administration of the drug (Von Hoff et al., 1979;
Krakoff, 1979). In particular, the dose-limiting factor of cis-
platin depends on its nephrotoxicity-inducing activity (Kra-
koff, 1979). For this reason, development of cisplatin anologs
with less nephrotoxicity-inducing activity has been attempted
(Burchenal et al., 1979; Connors et al., 1979; Prestayko et al.,
1979; Lelieveld et al., 1984). At present, carboplatin, one of
such analogs, is available in the clinic.
A new platinum complex, 2-aminomethylpyrrolidine
(1,1-cyclobutanedicarboxylato)platinum(II) monohydrate
(DWA2114), has been demonstrated to have pronounced
antitumour effects against various rodent tumours, and has
proved to be less toxic in the kidney than cisplatin (Endoh et
al., 1989). Subsequently, it has been clarified that DWA2114
still has slightly increased urinary protein and sugar as
indicators for nephrotoxicity in mice (unpublished data).
There are two enantiomeric isomers, (-)-(R)-2-aminomethyl-
pyrrolidine(1,1-cyclobutanedicarboxylato)platinum(II) mono-
hydrate (DWA2114R) and (+)-(S)-2-aminomethylpyrrolidine
(1,1-cyclobutanedicarboxylato)platinum(II) monohydrate
(DWA2114S) (Figure 1), since DWA2114 contains an asym-
metric carbon in its carrier ligand. In general, it is well
known that stereo or enantiomeric isomers exhibit different
effects (Zimmerman & Feldman, 1981). With regard to
platinum complexes, Kidani et al. (1978) also reported that
the conformational difference on the carrier ligand of 1,2-
diaminocyclohexane platinum complexes resulted in different
antitumour activity. Accordingly, DWA2114R and
DWA2114S were synthesised and their antitumour effects
0 is
--NH2 /O-C> NPt H20
HNHO-C
DWA21 14R
DWA21 14S
Figure 1 Chemical structures of DWA2114R and DWA2 114S.
and nephrotoxity-inducing activities were compared. The
results obtained reveals that DWA2114R shows only an
antitumour effect, with no nephrotoxicity-inducing activity.
Materials and methods
Drugs
DWA2114R, DWA2114S and carboplatin were synthesised
in our laboratory. Cisplatin was purchased from Aldrich
Chemical Company, Inc. These drugs were dissolved in 0.9%
NaCl solution immediately before use.
Animals
Male BDF, and CDF, mice, 6-8 weeks of age, and male SD
rats, 5 weeks of age, were purchased from Charles River
Japan and Clea Japan, Inc., respectively.
Tumours and cells
L1210 leukaemia was maintained in DBA/2 mice by weekly
transfer of ascitic cells. Colon 26 carcinoma was maintained
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in serial passage by s.c. inoculation of the tumour b!ock into
the flank of Balb/c mice. Two normal rat kidney cell lines,
NRK49F and NRK52E cells were obtained from American
Type Culture Collection. They were cultured in RPMI me-
dium containing 10% FCS, 50 jLM 2-mercaptoethanol and
kanamycin (87 mg 1-'). Normal rat spleen cells were pre-
pared from spleens of male SD rats. Red blood cells con-
taminated in the splenocyte preparation were removed by the
hemolysation with 0.017M Tris (pH 7.6) containing 0.75%
NH4Cl.
Antitumour effect
BDF, or CDF, mice were inoculated i.p. with 106 L1210
leukaemia cells. Mice were injected i.p. with the drugs 24 h
after the tumour inoculation and the survival time of the
treated mice was recorded. In the case of Colon 26 car-
cinoma, CDF, mice were inoculated s.c. in the flank with
2-3 mm3 blocks of the tumour. The mice were given single
i.p. injection of the drugs 4 days after the tumour inocula-
tion. The tumours were removed and weighed on day 14
after the tumour inoculation . The efficacy of the given drug
was expressed as increase in life span (ILS) or growth
inhibitory ratio (GIR) by the following formulas:
[Mean survival time of treated mice 1 ILS(%)= I-I xlOO0
Mean survival time of control mice
G Mean tumour weight of treated mice ]
GIR (%)= 1- xl100
Mean tumour weight of control mice
Nephrotoxicity
After i.p. injection of the isomers into BDF, mice at the dose
indicated in the figures, sera was collected on days 3 and 5,
and blood urea nitrogen (BUN) was measured by means of
Unikit-BUN-s using Rapid-Blood Analyzer (Chugai Pharma-
ceutical Co. Ltd., Tokyo, Japan). Protein and sugar in the
urine collected at regular time intervals were determined
using BM test 8-IT paper test (Boehringer-Mannheim Japan
Co. Ltd., Tokyo, Japan).
Tissue distribution ofPt
BDF, mice were injected i.p. with the isomers at the dose
indicated in the figures. At 2, 24 h or 7 days after injection of
the drugs, plasma was collected and tissues including kidney,
heart, liver, lung and spleen were removed. In the case of
rats, plasma and these tissues were collected 2 h after SD rats
were injected i.v. with the drugs at a dose of 40mg kg-'.
Plasma and tissue samples were stored at - 30°C until
measurement of Pt content.
Drug uptake
Normal rat splenocytes, NRK49F and NRK52E cells which
were the only available cell lines were suspended in RPMI
medium containing kanamycin at a density of 4 x 106
cells ml-. The cell suspensions (total 5-50 ml) were exposed
to 50 ji M of the drugs at 37°C for 2 h with 5% CO2 in a
humidified atmosphere. The cells were then collected by cen-
trifugation and washed with PBS(-) three times. The cell
pellets were stored at -30°C until measurement of Pt con-
tent.
Pt determination
Pt concentrations in plasma and tissues were determined by a
modified method of Pera & Harder (1977). Briefly, plasma
and tissue samples were lyophilised and mixed with concen-
trated HNO3. In the case of cell pellets, they were directly
mixed with concentrated HNO3. They were digested in a hot
block bath, then evaporated until dry. Each residue was
solubilised in 0.1 N HNO3 and estimated for Pt by flameless
atomic absorption spectrophotometry using an atomic ab-
sorption spectrophotometer model AA-8500 MK II (Nippon
Jarrell-Ash Co. Ltd., Kyoto, Japan) or IL Video 12 (Allied
Analytical Systems, MA, USA) equipped with a heated
graphite furnace.
Results
Antitumour effect
The antitumour effects of the isomers against L1210 leu-
kaemia are shown in Table I. Both drugs were active against
L1210 and the mean survival time of the mice increased
in a dose-dependent manner. DWA2114R and DWA2114S
showed ILS values of 108- 110% maximally. The ILS of
DWA2114S was slightly higher than that of DWA2114R at
the same dose, but the difference was not statistically
significant except at doses of 20-40mgkg-'. A similar re
sult was obtained against Colon 26 carcinoma (Table II).
DWA2114R and DWA2114S exhibited high GIR values of
89-91% at a dose of 60mgkg-' by single i.p. injection.
In addition, the antitumour effect of DWA2114R against
L1210 leukaemia was compared with those of cisplatin and
carboplatin at 1/2LD,0 (Table III). Cisplatin was the most
active and certain cisplatin-treated mice were observed to
survive for a long term. DWA2114R was more effective
compared with carboplatin.
Nephrotoxicity
The nephrotoxicity-inducing activities of the isomers were
analysed using BDF, mice. Table IV shows BUN values on
day 3 and 5 after drug administration. BUN levels of mice
treated with DWA2114R at a dose of 100 mg kg-' were not
different from those of the normal mice. Toxic death
was observed in the group treated with DWA2114R at
120 mg kg-' and the BUN level of one surviving mouse
increased slightly on day 5. On the other hand, BUN levels
slightly but significantly increased on day 3 and severely
increased on day 5 in the treated group with DWA2114S at
doses of 70-80 mg kg-' and toxic death was observed
at 80 mg kg-'. Figure 2 shows time-dependent changes
in protein and sugar levels detected in the urine. In the
DWA2114S-treated mice, urinary protein and sugar increas-
ed on either day 2 or 3 at doses of more than 60 mg kg-'.
While, there was no increase in urinary protein and sugar
even at 120 mg kg-' in the DWA2114R-treated mice.
Pt concentrations in plasma and tissues
To account for the difference in nephrotoxicity-inducing
activities between the isomers, Pt concentrations in plasma
and a few selected tissues were determined at 2 h following
i.p. injection of DWA2114R or DWA2114S at a dose of
80 mg kg-' in BDF, mice (Figure 3). At 2 h after an adminis-
tration of DWA2114S, the kidney had the highest concentra-
tion of Pt (88.1 jgg-1 tissue wet weight), compared with
liver, spleen, lung, heart, or plasma. However, in the tissues
of DWA2114R-treated mice, the highest Pt level was ob-
served in the liver at 2 h after administration (19.1 jgg-'
tissue wet weight). Pt concentration in the kidney was
16.5 igg-' tissue wet weight also at 2 h after administration,
and this was somewhat lower than that in the liver of
DWA21 R-treated mice.
Pt levels of all the tissues and plasma were higher in
DWA2114S-treated mice than in DWA2114R-treated mice.
In particular, renal Pt concentration in the DWA2114S-
treated group was more than 5-fold that in the DWA2114R-
treated group. As shown in Figure 4, a similar marked
difference between renal Pt levels of the mice treated with the
isomers was observed at 24 h and even 7 days after adminis-
tration. On the other hand, in the liver, lung, spleen, heart,
and plasma, Pt concentrations in DWA2114S-treated mice
were less than 3-fold those in the corresponding tissues and
plasma of DWA2114R-treated mice. Figure 5a shows PtPROPERTIES OF DWA2114R AND ITS ISOMER 43
Table I Antitumour effects of DWA2114R and DWA2114S against L1210 leukaemia
Generalised
Dose Survival time (day) Wilcoxon ILS Number
Compounda (mgkg-') Median Range test (%) ofmice
0.9% NaCl solution 8 7-8 7
DWA2114R 20 12 8-12 P<0.01 39 5
40 12 12- 13 P<0.01 57 5
60 16 13- 17 P<0.01 92 5
80 16 15-19 P<0.01 108 5
100 15 13-17 P<0.01 92 5
DWA2114S 20 14 13- 15 P<0.01 77 5
40 15 13-23 P<0.01 105 5
60 16 14-22 P<0.01 110 5
80 16 14- 19 P<0.01 108 5
aDrugs were administered on day 1 as a single i.p. injection in male BDF, mice inoculated i.p.
with 106 L1210 cells on day 0.
Table II Antitumour effects of DWA2114R and DWA2114S against Colon 26
carcinoma
Dose Mean tumour weight Student's GIR
Compounda (mgkg-') on day 14 (mg)b t-test (0)
0.9% NaCI solution 1451 ± 178
DWA2114R 30 537 173 P<0.01 63
60 154 34 P<0.001 89
DWA2114S 30 425 88 P<0.001 70
60 136 29 P<0.001 91
aDrugs were administered on day 4 as a single i.p. injection in male CDF, mice (n = 5)
inoculated s.c. with the blocks of Colon 26 tumour on day 0. 'Mean ± s.e.
Table III Antitumour effects of DWA2114R, cisplatin and carboplatin against L1210
leukaemia at 1/2LDIO
Generalised
Dose Survival time (day) Wilcoxon ILS Long-term
Compounda (mgkg-') Median Range test (%) survivorb
Non-treat 8 7- 8 0/7
DWA2114R 48 14 13-18 P<0.01 91 0/7
Cisplatin 8.7 14 12->28 P<0.01 > 128 2/6
Carboplatin 71 13 12-18 P<0.01 76 0/7
aDrugs were administered on day 1 as a single i.p. injection in maleCDF1 mice inoculated i.p.
with 106 L1210 cells on day 0. LDIo ofDWA2114R, cisplatin and carboplatin are 95.3, 17.3 and
142 mg kg-', respectively. bNumber of 4 weeks-survivor/Number of treated mice.
Table IV Comparison of BUN levels following i.p. injection of
DWA2114R and DWA2114S in BDF1 mice
Dose BUN (mg dlI
Compound (mgkg-') Day 3 Day 5
Exp. 1
0.9% NaCl solution 17.0 ± 1.2 14.5 ± 2.2
DWA2114R 60 13.8 0.9 13.8 ± 3.9
DWA2114S 60 17.7± 1.6 15.4±2.7
Exp. 2
0.9% NaCI solution 14.2 ± 1.1 _b
DWA2114R 100 14.9± 1.5 19.9± 2.4
120 15.8±2.1 35.6c
DWA2114S 70 32.8 ± 7.2 59.3 ± 6.9
(P<0.05) (P<0.001)
80 32.1 ± 5.3 70.6 ± 9.8d
(P<0.05) (P<O.001)
aMean + s.e., n = 4. Statistical analysis wascarried out by Student's
t-test(Exp. 1: versuseachcontrol, Exp. 2: versuscontrol onday 3). bNot
tested. Cn = 1. Toxic death was observed until day 5. dn = 2. Toxic death
was observed until day 5.
concentration in kidney 2 h following i.p. injection of
DWA2114R or DWA2114S at doses of 60-120mgkg -' in
BDF1 mice. Pt concentrations of kidney increased in a dose-
dependent manner in both groups. Pt concentration in kid-
ney was 3-5 fold in the DWA2114S-treated group at each
dose. In the group treated with DWA2114R 120mg kg',
renal Pt concentration was 31.7,Lg g-' tissue wet weight,
which was about half compared with renal Pt concentration
of DWA2114S 60 mg kg-i-treated. Such a difference between
renal Pt levels of the mice treated with the isomers was not
due to the difference in plasma Pt levels, because the Pt level
in the plasma of DWA2114S-treated mice was only 1.1-1.7
fold that of DWA2114R-treated mice (Figure Sb).
An additional experiment on tissue distribution in rats was
performed to examine whether the difference in tissue dis-
tribution was also observed in (1) other species and (2) i.v.
administration of the isomers. A similar difference in tissue
distribution was observed in rats treated i.v. with the drugs at
40 mg kg-' (Figure 6). Renal Pt content in kidney 2 h after
injection of DWA2114S was 3.8-fold higher compared to that
of DWA2114R.44 T. MATSUMOTO et al.
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Figure 2 Comparison of urinary protein and sugar following i.p.
injection of DWA2114R and DWA2114S in BDF, mice. The
upper and lower figures represent changes of urinary protein and
sugar, respectively, 100 (0) and 120 (A) mg kg-' of DWA2114R
or 60 (0) and 80 (A) mg kg-' of DWA2114S were injected into
mice. Each point represents the data of each set of mice. Urinary
protein and sugar were determined by test paper. The amount of
urinary protein or sugar was expressed with the following
criteria. Urinary protein; +, < 30 mg dl-' (normal level); + +,
< I00mgdlh'; + ++, 500mgdl'; + + + +, >500mg-
dl-'. Urinary sugar; -, not detected (normal level); +, < 100
mgdl-'; + +, < 300mgdl'; + ++, 000mgdl';
++++, >lOOOmgdl-'.
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Figure 4 Pt concentration in kidney following i.p. injection of
DWA2114R and DWA2114S (80mg kg-') in BDF, mice. The
number ofmice was three except in the column of DWA2114R at
2 h (n = 2). Bars, s.e. DWA2114R; M DWA2114S.
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Figure 3 Pt concentrations of tissues and plasma 2 h after i.p.
injection of DWA2114R and DWA2114S (80mg kg-') in BDF,
mice. The number of mice was two (DWA21 14R) or three
(DWA2114S). Bars, s.e., DWA2114R; M DWA2114S.
Drug uptake
To account for the difference between the isomers in Pt
accumulation in tissues, a study of uptake of the drugs into
cells was performed in vitro. Two normal rat kidney cell lines
NRK49F and NRK52E, and normal rat splenocyte were
exposed to 501 M of the drug at 37C for 2 h. DWA21 14S-
treated cells contained much more Pt (1.5-3 fold) compared
to DWA2114R (Table V). This difference was more distinct
in NRK cells than in splenocytes.
Dose (mg kg-')
Figure 5 Pt concentrations of kidney a, and plasma b, 2 h after
i.p. injection of DWA2114R and DWA2114S (60-120 mg kg-')
in BDF, mice. The number of mice was three except in the
columns of DWA2114R lOOmgkg-' and DWA2114S 80mg
kg-' (n=2). Bars, s.e. DWA2114R; 1 DWA2114S.
Discussion
In the antitumour experiments, both isomers showed marked
antitumour effects against the murine tumours. DWA2114S
was slightly more active than DWA21 14R against L1210 and
Colon 26 tumours at the same dose.
In contrast to the antitumour effects, the isomers showed
different effects on the kidney. Bodenner et al. (1986) have
reported that the peak BUN value in mice treated i.p. with
cisplatin at MTD was more than 5-fold that in the normal
control. We also found in this study that the increase in
BUN (4-fold) was observed on day 5 after administration
of DWA21 14S 70-80mg kg-'. In the mice treated with
DWA2114S at 60mgkg-', the increase in BUN level was
not observed but urinary protein and sugar had already
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Figure 6 Pt concentrations of tissues and plasma 2 h after i.v.
injection of DWA2114R and DWA2114S (40 mg kg-') in SD rats.
The number of rats was three. Bars, s.e. =l DWA2114R; M
DWA2114S.
Table V Pt content in the normal rat kidney cells and splenocytes
following 2 h exposure to DWA2114R and DWA2114S (50gM) at
37°C
Cell Compound Pt (ng 10' cells)a
NRK49F DWA2114R 76.7
DWA2114S 185 (2.4)b
NRK52E DWA2114R 54.6
DWA2114S 153 (2.8)
Splenocyte DWA2114R 2.05
DWA2114S 2.98 (1.5)
aValues arethemeanofduplicates. bPtcontentinDWA2114S-treated
cells/Pt content in DWA2114R-treated cells.
increased. On the other hand, no increases in BUN or
urinary protein and sugar were observed in the mice treated
with DWA2114R even at 100mg kg-'. It is worthy of men-
tion that each isomer has a different effect on the kidney and
that DWA2114R showed no nephrotoxicity, in contrast to
DWA2114S.
The main tissue which accumulates Pt in cisplatin-treated
animals is the kidney (Litterst et al., 1976). In the case of
DWA2114S, tissue distribution was similar to that of cis-
platin and the highest Pt concentration was also found in the
kidney. However, the kidney of DWA2114R-treated mice
contained a much lower Pt concentration than that of
DWA2114S-treated mice. In the experiments using cisplatin-
treated animals (Cvitkovic et al., 1977; Ward et al., 1977;
Osman et al., 1984), it has been observed that the severity of
renal toxicity correlates with renal Pt concentration and that
coadministration ofcisplatin and diuretics causes decreases in
renal Pt concentration and in BUN. Those results indicate
that the high content of Pt in the kidney causes nephrotox-
icity with the increase in BUN. Therefore, the fact that there
was no increase of BUN in DWA2114R-treated mice could
have been brought about by the low content of Pt in the
kidney, and this also might explain the reason why there
were no side effects of DWA2114R in the kidney. Further-
more, the difference in accumulation of Pt in the kidney was
also observed in rats treated with the drugs given by i.v.
administration the way platinum complexes have been clini-
cally used. Since this difference was not dependent on an
administration route of the drugs or species, DWA2114R is
expected to show no nephrotoxicity in humans.
The results of drug uptake into normal kidney cells and
splenocytes indicate that it was easier for DWA2114S to
accumulate in the cell than it was for DWA21 14R. The
results that the difference in uptake of the isomers was more
distinct in the kidney cells and that drug uptake in the kidney
cells was higher than in the splenocytes are consistent with
the results of tissue distribution in vivo. This difference
between the isomers in uptake into the cell is probably one
reason for the difference in tissue distribution. It is interesting
why the isomers showed different accumulation in the cell,
especially in the kidney cell. We have found no difference
between the isomers in binding activities to DNA or plasma
protein in vitro (data not shown). One possible explanation is
that it may be easier for DWA2114S to enter the cells than
for DWA2114R. There have been many instances in which
membrane transport is different between stereo or enan-
tiomeric isomers requiring a carrier molecule for transport
into the cell (Zimmerman & Feldman, 1981). For instance,
some anticancer agents, such as nitrogen mustard and mel-
phalan, are known to be transported into the cell by mem-
brane carriers (Goldenberg et al., 1970; Vistica et al., 1978).
Byfield & Calabro-Jones (1981) showed that the uptake of
cisplatin also seemed to depend on a membrane transport
mechanism. Ifwe assume that the uptake of DWA21 14R and
DWA2114S to the cell depends on a membrane carrier, it is
possible that the isomers interact differently with a membrane
carrier so that a difference in uptake of the drugs occurs.
Other possibilities, such as differences in affinities to meta-
bolic enzyme or glutathion, and differences in efflux from the
cell, cannot be ruled out. Further studies regarding the
molecular mechanisms are needed to exactly explain the
difference of nephrotoxicity between the isomers.
With respect to DWA2114R, the results in this study
revealed that DWA21 14R exhibited equivalent or greater
antitumor activity compared with carboplatin, and no neph-
rotoxicity, unlike cisplatin. These results suggest that DWA-
2114R could be a promising new platinum anticancer agent.
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